{"disease":{"id":"newly-diagnosed-secondary-or-high-risk-aml","name":"newly diagnosed secondary or high risk aml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04230239","title":"Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"PETHEMA Foundation","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}